are shareholders of ImmuPharma PLC, the parent company of UREKA Sarl
Semaglutide, like any medication, can cause reactions, and tracking these can guide whether your dose should be increased, decreased, or maintained

Citt Della Salute e Della Scienza Di Torino, University of Turin, Turin, Italy, (4)University of Milano-Bicocca, (5)Division of Hepatology, Ospedale San Giuseppe, Universit Di Milano, (6)Translational and Precision Medicine, Sapienza University of Rome, Italy, (7)Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, Italy, (8)Humanitas University, Rozzano (MI), MI, Italy, (9)Humanitas University, Rozzano (Milan), Italy, Division of Internal Medicine and Hepatology, Humanitas Clinical Research Center Ircss, (10)Division of Gastroenterology and Hepatology, Foundation Irccs Ca Granda Ospedale Maggiore Policlinico, Milan, Italy, (11)Hepatology and Gastroenterology, Asst GOM Niguarda, (12)University of Genova, Genova, Italy, (13)Ospedale Policlinico San Martino, Genova, (14)Gastroenterology Unit, Santa Maria Delle Croci Hospital, Ravenna, Italy, (15)Division of Gastroenterology, National Institute of Gastroenterology S De Bellis, Castellana Grotte, Bari, Italy, (16)Fondazione a Gemelli Hospital Irccs, Internal Medicine, Gastroenterology, Hepatology, (17)Gastroenterology Unit, Fondazione Casa Sollievo Della Sofferenza Irccs San Giovanni Rotondo, (18)Gastroenterology Unit, Fondazione Casa Sollievo Della Sofferenza Irccs, San Giovanni Rotondo (Foggia), Italy, (19)Internal Medicine, Asst Lecco Hospital, (20)University of Cagliari, (21)Internal Medicine, Ospedale Barletta, (22)Hepatology Unit, Pescara General Hospital, (23)Liver Unit, Arnas Garibaldi, Catania, Italy, (24)Gastroenterology and Hepatology Unit, Policlinico-Vittorio Emanuele, (25)Hospital Universitario 12 De Octubre, Madrid, (26)Hospital Universitario Reina Sofia, Cordoba, (27)Complexo Hospitalario Universitario De Santiago, Corua, (28)Madrid, (29)Spain, (30)Hospital Universitario La Fe, Valencia

Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural [PMID: 36335114] Laboratory literature summary: Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural antagonist